OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.

RegulatoryapprovedOMLYCLOXOLAIRPositive

AI Analysis

Summary

OMLYCLO (omalizumab-igec), the first FDA-approved interchangeable biosimilar to XOLAIR, is now commercially available in the U.S. across all four approved indications.

Outcome Details

FDA-approved interchangeable biosimilar to XOLAIR, now commercially available

Importance:7/10

Sentiment:

0.80

biosimilarFDA approvalinterchangeablecommercial launchomalizumab

Related Companies

$SDZ.SW $NVS

Read the original article

Published by PR Newswire Biotech on October 5, 2026 12:45 PM

Read Original